Network analysis of gene expression in mice provides new evidence of involvement of the mTOR pathway in antipsychotic-induced extrapyramidal symptoms

To identify potential candidate genes for future pharmacogenetic studies of antipsychotic (AP)-induced extrapyramidal symptoms (EPS), we used gene expression arrays to analyze changes induced by risperidone in mice strains with different susceptibility to EPS This study is a part of a convergent functional genomic approach that plans to integrate the data presented here with: data from gene expression analysis of neuroblastoma cell line under treatment with risperidone; and data from gene expression analysis of peripheral blood from first psychotic patients treated with risperidone. Gene expression was assessed by microarray (Affymetrix GeneChip® Arrays MG 430 PM) in mice treated with risperidone 1mg/kg for three consecutive days为筛选可用于抗精神病药物（antipsychotic, AP）诱导的锥体外系症状（extrapyramidal symptoms, EPS）药物基因组学未来研究的潜在候选基因，本研究采用基因表达芯片技术，分析利培酮对不同锥体外系症状易感性小鼠品系的诱导表达变化。本研究属于整合功能基因组学研究方案的一部分，该方案计划将本研究提供的数据与以下两类数据进行整合：一是利培酮处理后神经母细胞瘤细胞系的基因表达分析数据；二是接受利培酮治疗的首发精神病患者外周血的基因表达分析数据。本研究通过微阵列（Affymetrix GeneChip® 阵列MG 430 PM），对连续3天每日以1mg/kg剂量接受利培酮处理的小鼠进行基因表达检测。